Literature DB >> 31013095

Polydopamine-Decorated Orlistat-Loaded Hollow Capsules with an Enhanced Cytotoxicity against Cancer Cell Lines.

Xiaqing Zhou1, Tzu-Lan Chang1, Shuang Chen1, Tianchi Liu1, Haoyu Wang1, Jun F Liang1.   

Abstract

Orlistat, an FDA-approved antiobesity drug, has recently been shown to have anticancer effects. However, orlistat is extremely hydrophobic with low absorption. Therefore, new approaches are needed to effectively deliver orlistat for cancer therapy. Herein, we developed a fast and simple method to use polydopamine-coated hollow capsule (PHC) as a drug nanocarrier for enhancing the therapeutic effects of orlistat. Orlistat-loaded PHC had an average size of 200 nm, which was characterized by using dynamic light scattering and scanning electron microscope. Furthermore, the polydopamine layer provided an excellent control of orlistat release because it was extremely sensitive to pH values. The cellular uptake and cytotoxicity experiments were performed to show that orlistat packaged in PHC could be endocytosed into cells and then significantly improved the cytotoxic activity against cancer cell lines in a short time compared with free orlistat. Moreover, dynamic study of cell membrane lysis was performed by staining with the LIVE/DEAD kit to demonstrate the cancer-killing mechanism. The size of the cell surface area has also been proven to be a key parameter which affected drug efficacy. Taken all together, these results present that orlistat-loaded PHC is a very promising formula for cancer treatments.

Entities:  

Keywords:  cancer therapy; controlled release; hollow capsule; nanoparticle; orlistat; polydopamine

Mesh:

Substances:

Year:  2019        PMID: 31013095     DOI: 10.1021/acs.molpharmaceut.9b00116

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  1 in total

Review 1.  Nanoparticles modified by polydopamine: Working as "drug" carriers.

Authors:  Anting Jin; Yitong Wang; Kaili Lin; Lingyong Jiang
Journal:  Bioact Mater       Date:  2020-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.